SDC1 and fetal growth restriction: Indeed, altered placental expression of proteoglycans (e.g., syndecan-1; endocan, glypican-3) was reported in obstetrical syndromes, such as pre-eclampsia [19,20,21], fetal growth restriction [22,23,24], and gestational diabetes mellitus [25,26], pointing to their potential roles in the development of these syndromes.